Cargando…
Retraction: ‘HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2’ (2019), by Ye et al.
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Royal Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485898/ https://www.ncbi.nlm.nih.gov/pubmed/37681498 http://dx.doi.org/10.1098/rsob.230322 |
Ejemplares similares
-
HOXD-AS1 confers cisplatin resistance in gastric cancer through epigenetically silencing PDCD4 via recruiting EZH2
por: Ye, Yafei, et al.
Publicado: (2019) -
TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2
por: Xu, Caihui, et al.
Publicado: (2018) -
EZH2 Contributes to 5-FU Resistance in Gastric Cancer by Epigenetically Suppressing FBXO32 Expression [Retraction]
Publicado: (2023) -
Retracted: lncRNA HOTTIP Recruits EZH2 to Inhibit PTEN Expression and Participates in IM Resistance in Chronic Myeloid Leukemia
por: International, Stem Cells
Publicado: (2023) -
Retracted: Knockdown of lncRNA HOXD-AS2 Improves the Prognosis of Glioma Patients by Inhibiting the Proliferation and Migration of Glioma Cells
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)